STEPWISE结构化生活方式教育随机对照试验
该随机对照试验在英格兰十家精神卫生机构招募414名精神分裂症、分裂情感性障碍或首发精神病成人,比较STEPWISE团体结构化生活方式教育与常规治疗。12个月时两组体重变化无差异(均差0.0 kg,95%CI -1.6至1.7,P=0.963),体力活动、膳食摄入及生化指标均未改变,干预从医疗保健角度不具成本效果。
要点
- STEPWISE干预未能在12个月时减轻精神分裂症谱系障碍患者体重。
- 体力活动、膳食摄入及生化指标在干预组与常规治疗组间均无变化。
- 干预从医疗保健角度每获得一个质量调整生命年增量成本为246 921英镑,不具成本效果。
核心结论
- STEPWISE结构化生活方式教育项目对精神分裂症谱系障碍患者既无临床效果也无成本效果。
研究设计与样本
- 随机对照试验(注册号ISRCTN19447796),从英格兰十家精神卫生机构招募成人精神分裂症、分裂情感性障碍或首发精神病患者414例(干预组208例,常规治疗组206例)。
- 12个月干预包括四次每周2.5小时团体课程,随后每两周维持接触及第4、7、10个月团体课程;主要结局为12个月后体重变化。
主要发现
- 341例(84.4%)完成试验;12个月时体重降低组间无差异(均差0.0 kg,95%CI -1.6至1.7,P=0.963)。
- 体力活动、膳食摄入及生化指标均无改变。
- STEPWISE干预受到参与者与实施者好评。
关键数值与推荐
- 主要结局体重变化均差0.0 kg(95%CI -1.6至1.7,P=0.963)。
- 医疗保健角度增量成本效果比为每质量调整生命年246 921英镑。
临床怎么用
- 该结构化团体生活方式教育方案不宜作为常规临床实践中的有效减重干预推广。
- 临床仍需探索其他有效管理精神分裂症患者超重与肥胖的方法。
局限性
- 原文未报告针对干预无效果的具体局限性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is a major challenge for people with schizophrenia.AimsWe assessed whether STEPWISE, a theory-based, group structured lifestyle education programme could support weight reduction in people with schizophrenia. METHOD: In this randomised controlled trial (study registration: ISRCTN19447796), we recruited adults with schizophrenia, schizoaffective disorder or first-episode psychosis from ten mental health organisations in England. Participants were randomly allocated to the STEPWISE intervention or treatment as usual. The 12-month intervention comprised four 2.5 h weekly group sessions, followed by 2-weekly maintenance contact and group sessions at 4, 7 and 10 months. The primary outcome was weight change after 12 months. Key secondary outcomes included diet, physical activity, biomedical measures and patient-related outcome measures. Cost-effectiveness was assessed and a mixed-methods process evaluation was included. RESULTS: Between 10 March 2015 and 31 March 2016, we recruited 414 people (intervention 208, usual care 206) with 341 (84.4%) participants completing the trial. At 12 months, weight reduction did not differ between groups (mean difference 0.0 kg, 95% CI -1.6 to 1.7, P = 0.963); physical activity, dietary intake and biochemical measures were unchanged. STEPWISE was well-received by participants and facilitators. The healthcare perspective incremental cost-effectiveness ratio was £246 921 per quality-adjusted life-year gained. CONCLUSIONS: Participants were successfully recruited and retained, indicating a strong interest in weight interventions; however, the STEPWISE intervention was neither clinically nor cost-effective. Further research is needed to determine how to manage overweight and obesity in people with schizophrenia.Declaration of interestR.I.G.H. received fees for lecturing, consultancy work and attendance at conferences from the following: Boehringer Ingelheim, Eli Lilly, Janssen, Lundbeck, Novo Nordisk, Novartis, Otsuka, Sanofi, Sunovion, Takeda, MSD. M.J.D. reports personal fees from Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, Janssen, Servier, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals International Inc.; and, grants from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, Janssen. K.K. has received fees for consultancy and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Servier and Merck Sharp & Dohme. He has received grants in support of investigator and investigator-initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Boehringer Ingelheim and Merck Sharp & Dohme. K.K. has received funds for research, honoraria for speaking at meetings and has served on advisory boards for Lilly, Sanofi-Aventis, Merck Sharp & Dohme and Novo Nordisk. D.Sh. is expert advisor to the NICE Centre for guidelines; board member of the National Collaborating Centre for Mental Health (NCCMH); clinical advisor (paid consultancy basis) to National Clinical Audit of Psychosis (NCAP); views are personal and not those of NICE, NCCMH or NCAP. J.P. received personal fees for involvement in the study from a National Institute for Health Research (NIHR) grant. M.E.C. and Y.D. report grants from NIHR Health Technology Assessment, during the conduct of the study; and The Leicester Diabetes Centre, an organisation (employer) jointly hosted by an NHS Hospital Trust and the University of Leicester and who is holder (through the University of Leicester) of the copyright of the STEPWISE programme and of the DESMOND suite of programmes, training and intervention fidelity framework that were used in this study. S.R. has received honorarium from Lundbeck for lecturing. F.G. reports personal fees from Otsuka and Lundbeck, personal fees and non-financial support from Sunovion, outside the submitted work; and has a family member with professional links to Lilly and GSK, including shares. F.G. is in part funded by the National Institute for Health Research Collaboration for Leadership in Applied Health Research & Care Funding scheme, by the Maudsley Charity and by the Stanley Medical Research Institute and is supported by the by the Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London.
引用
- Holt RIG, Gossage-Worrall R, Hind D, et al. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. Br J Psychiatry. 2018. PMID: 30251622. doi:10.1192/bjp.2018.167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。